Navigation Links
Tianyin Pharmaceutical Co., Inc. to Present at Rodman & Renshaw Annual Global Investment Conference in New York City on November 11, 2008 at 12:00 p.m. EST
Date:10/27/2008

CHENGDU, China, Oct. 27 /Xinhua-PRNewswire-FirstCall/ -- Tianyin Pharmaceutical, Co., Inc., (Amex: TPI), a manufacturer and supplier of modernized traditional Chinese medicine ("TCM") based in Chengdu, China, today announced that the Company will present at the Rodman & Renshaw Annual Global Investment Conference on Tuesday, November 11th, 2008. The Conference will be held on November 10th-12th at New York Palace Hotel in New York City.

The Company's presentation will take place in the Henry Salon (5th Floor) at 12:00 p.m. EST. Dr. Guoqing Jiang, Tianyin's Chairman and CEO, Mr. Allen Tang, assistant to the CEO, and Mr. Stewart Lor, a member of the Board of Directors, will be representing Tianyin at the conference and will be available for one-on-one meetings with analysts and investors throughout the day.

Management will discuss the Company's current product portfolio, development pipeline, research and development platform, recent financial highlights and its long term growth strategy.

Participation is by invitation and registration is mandatory. For more information on the conference contact your Rodman & Renshaw representative or visit http://www.rodmanandrenshaw.com.

About Tianyin Pharmaceuticals

Tianyin is a manufacturer and supplier of modernized Traditional Chinese Medicine ("TCM") in China. It was established in 1994 and acquired by the current management team in August 2003. It has a comprehensive product portfolio of 33 modernized TCMs and 4 generic western medicines in the market, 22 of which are listed in the highly selective National Medicine Catalog of the National Medical Insurance Program. Tianyin owns and operates two GMP manufacturing facilities and an R&D platform supported by leading Chinese academic institutions. The Company has a pipeline of 48 pharmaceutical products pending approval. Tianyin has an extensive nationwide distribution network throughout China with a sales force of 720 salespeople. Tianyin is headquartered in Chengdu, Sichuan Province with two manufacturing facilities and a total of 1,384 employees. Tianyin achieved revenue of approximately $33.5 million and net income of approximately $6 million in FY2008 ending June 30, 2008. For more information about Tianyin, please visit http://www.tianyinpharma.com

Safe Harbor Statement

This Press Release contains or may contain forward looking statements and information that are based upon beliefs of and information currently available to the Company's management as well as estimates and assumptions made by the Company's management. When used herein the words "anticipate", "believe", "estimate", "expect", "future", "intend", "plan" and similar expressions as they relate to the Company or the Company's management identify forward looking statements. These statements involve certain risks and uncertainties including but not limited to risks associated with the uncertainty of future financial results, additional financing requirements, development of new products, government approval processes, the impact of competitive products or pricing, technological changes, the effect of economic conditions and other uncertainties detailed in the Company's filings with the Securities and Exchange Commission. Should one or more of these risks or uncertainties materialize, or should the underlying assumptions prove incorrect, actual results may differ significantly from those anticipated, believed, estimated, intended or planned.

For more information, please contact:

For the Company:

Allen Tang, Ph.D., MBA, Assistant to the CEO

China 15821225642

Allen.y.tang@gmail.com

Investors:

HC International, Inc.

Alan Sheinwald

US (914) 669-0222

Alan.Sheinwald@hcinternational.net


'/>"/>
SOURCE Tianyin Pharmaceutical (TPI)
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Tianyin Pharmaceutical to Present at the Brean Murray All-Cap All-China Conference in New York City on May 20, 2008 at 10:15 a.m. EDT
2. Tianyin Pharmaceutical Announces SFDA Approval to Market Azithromycin Dispersible Tablets
3. Tianyin Pharmaceutical Appoints Three New Independent Board Members
4. Tianyin Pharmaceutical Co., Inc. Announces Second Quarter 2008 Financial Results
5. Tianyin Pharmaceutical, Inc. to Host 2008 Second Quarter Earnings Conference Call on Thursday, February 14, 2008 at 4:15 p.m. EST
6. Savient Pharmaceuticals to Hold Third Quarter 2008 Financial Results Conference Call on Thursday, November 6, 2008
7. BioCryst Pharmaceuticals To Announce Third Quarter 2008 Financial Results On October 31, 2008
8. Johnson & Johnson Pharmaceutical Research & Development, L.L.C. Submits New Drug Application to FDA for Carisbamate
9. Amylin Pharmaceuticals to Present at BIOCOM Investor Conference
10. Keryx Biopharmaceuticals Notified that Nasdaq Has Extended Minimum Bid Price Rule Compliance Period
11. Anadys Pharmaceuticals Reports Third Quarter 2008 Financial Results and Highlights
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/28/2017)... -- Summary This report provides all the ... partnering interests and activities since 2010. Description The Partnering ... into the partnering activity of one of the world,s leading ... prepared upon purchase to ensure inclusion of the most up ... will be delivered in PDF format within 1 working day ...
(Date:3/28/2017)... March 28, 2017  Viking Therapeutics, Inc. ("Viking") (NASDAQ: ... of novel therapies for metabolic and endocrine disorders, today ... , Ph.D., will deliver a corporate presentation at H.C. ... Conference, being held April 3, 2017 at the St. ... for this presentation are as follows: ...
(Date:3/28/2017)... ... March 28, 2017 , ... Currently symptomatic therapies for ... recent study published in STEM CELLS suggests that human neural stem cell (hNSC) ... to produce more neural cells. , Strategies involving transplantation of these cells ...
(Date:3/28/2017)... Triangle Park, NC (PRWEB) , ... March 28, ... ... development company engaged in the development of a new orally administered treatment for ... Advisory Board. , CEO John Didsbury states, “As we seek to uniquely treat ...
Breaking Biology Technology:
(Date:2/16/2017)... 2017  Genos, a community for personal genetic ... received Laboratory Accreditation from the College of American ... laboratories that meet stringent requirements around quality, accuracy ... "Genos is committed to maintaining the ... honored to be receiving CAP accreditation," said ...
(Date:2/13/2017)... SAN FRANCISCO , Feb. 13, 2017 /PRNewswire/ ... a centralized platform that is designed to enhance ... the latest release in the RSA Fraud & ... to enable organizations to leverage additional insights from ... anti-fraud tools to better protect their customers from ...
(Date:2/10/2017)... Research and Markets has announced the addition of ... Commercial Aspects" to their offering. ... Biomarkers play an important ... selection of treatment as well for monitoring the results. There ... modern medicine. Biochip/microarray technologies and next generation sequencing are also ...
Breaking Biology News(10 mins):